869 results about "Arthritis" patented technology

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses a citrullinated SAA polypeptide and application thereof in preparation of a rheumatoid arthritis diagnosis product, the amino acid sequence of the citrullinated SAA polypeptide is DKYFHA-Cit-GNYDAAK-Cit-GPGGA, through the polypeptide, the citrullinated autoantigen B cell epitope of SAA and a corresponding autoantibody, namely an anti-citrullinated SAA polypeptide antibody (anti-CAP), are identified. The expression level of anti-CAP in RA patients is obviously higher than that of other disease control groups and healthy groups, and the anti-CAP has better positive rate in early RA, ESR / CRP normal RA and anti-CCP antibody / RF negative RA, and provides a new strategy for diagnosis of RA.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention belongs to the technical field of intelligent diagnosis, and particularly relates to an AI combined MRI and clinical JIA diagnosis system and a storage medium. According to the system disclosed by the invention, the early auxiliary diagnosis of the juvenile idiopathic arthritis is carried out by combining artificial intelligence with multi-dimensional and multi-modal information of multi-sequence MRI images of knee joints of children and various clinical information. The main technology of the method is child knee joint tissue segmentation based on deep learning, a multi-dimensional feature extraction strategy based on a segmentation result, and disease classification based on multi-modal feature integration and deep learning. By integrating the multi-dimensional features of the multi-sequence MRI images and fusing different modal features such as image information and clinical information, an auxiliary diagnosis result with high accuracy can be provided. The technology provided by the invention is beneficial to the realization of early diagnosis and early treatment of juvenile idiopathic arthritis, and has a very good application prospect.

The invention discloses application of citrullinated endolectin-1 polypeptide in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the citrullinated endolectin-1 polypeptide is GD-Cit-WSSQQGSKAVYPE, and the amino acid sequence of the citrullinated endolectin-1 polypeptide is GD- The product is used for detecting the content of the anti-citrullinated endolectin-1 polypeptide antibody in a biological sample of a patient, and the antibody level is remarkably different from that of normal healthy people and other common rheumatism immune disease patients easily confused with rheumatoid arthritis in the body of an RA patient. The kit has good sensitivity for common RA, RA with normal ESR and CRP, and anti-CCP antibody / RF negative RA patients, and has good supplementary diagnostic value for RA diagnosis.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses a bacterial polypeptide Gfo and application thereof in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the bacterial polypeptide Gfo is LNSHGFLPETE. A diagnostic product prepared from the bacterial polypeptide Gfo can effectively detect that the level of an anti-bacterial polypeptide Gfo antibody in a biological sample of a rheumatoid arthritis patient is obviously higher than that of healthy people and other rheumatoid immune diseases similar to rheumatoid arthritis. In addition, in CCP antibody and RF negative patients, the increase is still significant. Therefore, the antibacterial polypeptide Gfo antibody is an important biomarker of rheumatoid arthritis, and provides an effective new method for diagnosis of RA, especially diagnosis of serum-negative RA.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention provides combination therapies comprising disease modifying anti-rheumatic drugs and mitochondrial complex I modulator (MCIM) compounds, which find utility in the medical field of inflammatory and progressive disorders, for example autoimmune diseases such as arthritis.

The invention discloses a lactobacillus rhamnosus capable of improving joint inflammation and promoting bone health, a metagen and application of the lactobacillus rhamnosus, the lactobacillus rhamnosus is lactobacillus rhamnosus BN02, the lactobacillus rhamnosus is preserved in China General Microbiological Culture Collection Center on November 27, 2023, and the preservation number is CGMCC No.29133. The lactobacillus rhamnosus can be used for improving joint inflammation and promoting bone health. The lactobacillus rhamnosus BN02 can reduce the number of gram-negative bacteria in intestinal tracts of arthritis patients, increase the synthesis amount of bone collagen, and is beneficial to promoting absorption of vitamin C by the intestinal tracts, improving joint inflammation and promoting bone health.

The invention belongs to the technical field of chemical drugs, provides an interleukin-17A / F inhibitor as well as a preparation method and application thereof, and particularly relates to a compound as shown in a general formula (I), or a racemate, an isomer or medicinal salt thereof, which is used for treating diseases such as psoriasis and arthritis as the IL-17A / F inhibitor.

The invention discloses a knee joint fraction prediction method and system fused with multi-modal image features. The knee joint fraction prediction method fused with the multi-modal image features obtains a knee joint prediction fraction of an object through five steps. The method has the beneficial effects that 1, deep learning, radiomics characteristics and combined clinical characteristics are fused, the magnetic resonance T1 sequence image of the knee joint is processed and analyzed, the popliteal artery ROI is marked, and related radiomics and deep network characteristics are extracted; compared with traditional single feature analysis, the method has the advantages that more comprehensive and accurate disease assessment is provided, and the accuracy and reliability of knee osteoarthritis prediction are improved. And 2, the method is based on the obvious relation between the popliteal artery and the knee bone joint, innovatively analyzes the image features of the popliteal artery and combines clinical data, so that the method not only can predict the occurrence and progress of the osteoarthritis more accurately in an earlier stage, but also obviously improves the prediction effect.

The present disclosure provides a compound of formula H having excellent PDE4B inhibitory activity, and a pharmaceutical composition thereof and a use thereof. The compound provided by the present disclosure can be used for effectively treating PDE4-related diseases and disorders, including but not limited to inflammatory respiratory diseases, inflammatory bowel diseases, inflammatory joint diseases, inflammatory skin diseases, inflammatory eye diseases, and diseases or cancers of the peripheral or central nervous system.

The invention relates to the technical field of digital health, in particular to a personalized rehabilitation exercise method for rheumatoid arthritis patients based on a BCW theory, which comprises the following steps: acquiring joint angle change and calculating a pain delay response coefficient, detecting fluctuation of supporting force and stabilizing force to obtain a joint load tolerance value, analyzing respiratory coordination to generate a respiratory coordination index, and performing rehabilitation training on the respiratory coordination index. The method comprises the steps that a joint angle sensor and pain intensity data are analyzed, a BCW capacity factor weight value is generated in a weighted mode, a fuzzy control algorithm is input to conduct hierarchical mapping adjustment on action amplitude frequency and rest intervals, and exercise adaptability feedback data are generated through monitoring completion degree and pain feedback. The exercise intensity is dynamically adjusted in real time through a data model, a personalized rehabilitation scheme is automatically optimized, the problems that subjective feedback is relied on, and physiological changes cannot be responded in time are solved, more accurate exercise amount adjustment is provided, the situation that the joint burden is increased due to improper exercise intensity is avoided, and the rehabilitation process is effectively promoted.

The invention relates to an application of a CTHRC1 inhibitor in preparation of a medicine for preventing and / or treating arthritis. Specifically, the invention provides application of an inhibitor or an antagonist of a CTHRC1 gene or a protein thereof, the inhibitor or the antagonist is used for preparing a composition or a preparation, and the composition or the preparation is used for (a) preventing and / or treating arthritis-related diseases; and / or (b) inhibiting cartilage cell senescence.

The invention provides an auxiliary system for a rheumatoid arthritis medication scheme. The auxiliary system is used for matching similar historical medication schemes, related medication costs and treatment results used for treating historical rheumatoid arthritis patients and judging whether transaminase abnormity occurs or not based on the treatment conditions of current patients, analyzing each historical medication scheme, and determining whether the transaminase abnormity occurs or not according to the analyzed historical medication schemes and the analyzed transaminase abnormity. And obtaining scores or grades of three dimensions of safety, effectiveness and economy of each historical medication scheme. And based on the requirements or tendencies of the patient on the medication schemes in three dimensions of safety, effectiveness and economy, screening out corresponding candidate medication schemes from the historical medication schemes and recommending the candidate medication schemes. According to the technical scheme, by means of the computer technology, the corresponding medication scheme is automatically recommended based on the medication tendency of the rheumatoid arthritis patient, decision assistance is provided, the time for adapting the medication scheme for the patient is saved, and the satisfaction degree of the rheumatoid arthritis patient to the medication scheme is improved.

The invention discloses an application of tiopronin wrapped by ROS (reactive oxygen species) response hydrogel in preparation of a medicine for treating osteoarthritis. The ROS response hydrogel is prepared from the following components: tiopronin; the compound group of lecithin and ketal thiol (TK) is TK-NH22, 2 '-(propane-2, 2-diyl bis (sulfanilamide diyl)) diethylamine (sulfanediyl), and the compound group of lecithin and ketal thiol (TK) is TK-NH22, 2'-(propane-2, 2-diyl bis (sulfanilamide diyl)); 12 wt% of methyl cellulose, Na2HPO4. 12H2O and xylitol; according to the hydrogel, controlled release of tiopronin is achieved through an ROS response group, mitochondrial autophagy is enhanced by up-regulating a Bnip3-Pink1-Parkin signal channel, oxidative stress is inhibited, and the progress of osteoarthritis is delayed; compared with the prior art, the invention has the advantages that: the invention discloses an osteoarthritis treatment medicine with the effects of resisting inflammation, relieving pain and inhibiting cartilage degeneration for the first time, and discloses a knee joint intracavity administration route of tiopronin for the first time. Particularly, the tiopronin targeted activation Bnip3-Pink1-Parkin signal channel provided by the invention has a remarkable effect in the aspect of inhibiting the progress of OA, which proves that the medicine has a strong effect on the treatment of osteoarthritis.

The invention discloses a risk assessment method for rheumatoid arthritis accompanied with cognitive impairment based on big data, and belongs to the field of data feature extraction, and the method specifically comprises the steps: carrying out the unified calling of collected clinical, laboratory and iconography features as an original feature set, and completing the preprocessing through multiple interpolation and Z-score standardization; inputting the original feature set into a self-attention network, and generating interaction feature representation for mining high-order interaction; low-dimensional potential feature vectors are compressed, and combined training is carried out through reconstruction and discriminant loss; inputting the potential feature vectors into an XGBoost model, and screening out a preliminary candidate feature subset; performing global and local importance evaluation on the candidate feature subsets by adopting SHAP, and iteratively rejecting features of which the contribution degrees are lower than a threshold value epsilon until the final feature subset is stable; and respectively inputting the final feature subsets into the simplified ResNet and LightGBM to obtain two groups of risk scores, and then generating a fusion risk score through weighted fusion.

The invention provides a rheumatoid arthritis patient low muscle quality risk prediction method based on an uncertainty perception stacked meta-learning structure, and belongs to the technical field of machine learning. The method comprises the following steps: acquiring a rheumatoid arthritis data set; constructing a base learner set comprising a table Transform class network and a gradient boosting tree class model; splicing the out-of-fold prediction probabilities of all the base learners and the statistics thereof to form a meta-feature matrix; taking the meta feature matrix as input, and constructing and training a meta learner comprising a spectrum normalization multilayer perceptron and a random feature Gaussian process output layer; collecting to-be-detected data, inputting the to-be-detected data into the trained base learner set and the trained meta learner in sequence, and performing temperature scaling and beta-calibration on a prediction result; and taking the calibrated prediction probability as a final prediction result. Through multi-source data fusion, the defects of an existing model in the aspects of practicability, probability reliability and the like are overcome.

The invention discloses a function-enhanced mesenchymal stem cell preparation obtained by utilizing arthritis effusion and hypoxia pretreatment of mesenchymal stem cells as well as a preparation method and application of the function-enhanced mesenchymal stem cell preparation, and relates to the technical field of biological medicines. The preparation method of the function-enhanced mesenchymal stem cell preparation obtained by utilizing arthritis effusion and hypoxia pretreatment of mesenchymal stem cells comprises the following steps: S1, obtaining mesenchymal stem cells and performing hypoxia amplification passage; s2, pretreatment of arthritis effusion; S3, pre-stimulation of the arthritis effusion of the mesenchymal stem cells to obtain function-enhanced mesenchymal stem cells; s4, index detection and screening; s5, preparing a function-enhanced mesenchymal stem cell preparation; optimized low-oxygen pretreatment is adopted, so that the cell activity is improved; the mesenchymal stem cells subjected to joint pretreatment of arthritis effusion and hypoxia enhance expression and secretion of anti-inflammatory factors and immunomodulatory molecules in the cells; the pre-stimulated mesenchymal stem cells show a stronger immunosuppression function in vitro.

A composition is described comprising a mixture of at least one cetylated fatty acid or a mixture of cetylated fatty acids and an antioxidant in reduced percentages by weight, and related methods for treatment of arthritis and of inflammatory joint and musculoskeletal pain. Furthermore a composition is described comprising a mixture of at least one cetylated fatty acid or a mixture of cetylated fatty acids and, optionally, an antioxidant, and related treatment methods for protecting the gastric mucosa and for regulating the blood glucose levels. Additionally, a method is described for preparing the at least one cetylated fatty acid or mixture of cetylated fatty acids and for preparing compositions comprising the cetylated fatty acids and the antioxidant.